The value of serum p53 antibody as a biomarker in oral and pharyngeal squamous cell carcinoma

Shotaro Hirokawa,Koji Araki,Taku Yamashita,Kosuke Uno,Masayuki Tomifuji,Hideaki Shimada,Akihiro Shiotani
DOI: https://doi.org/10.1080/00016489.2023.2165144
Abstract:Background: The development of more sensitive biomarkers for the detection of early-stage head and neck squamous cell carcinoma is needed. Aims/objectives: This study was performed to assess the value of serum p53 antibody (s-p53-Ab) as a biomarker for oral and pharyngeal carcinoma. Material and methods: Pre-treatment serum was collected for 71 patients with oral and pharyngeal carcinoma and 117 healthy volunteers as controls and analyzed s-p53-Ab using enzyme-linked immunosorbent assay (ELISA). Results: Using 1.3 U/mL as the cut-off value, 14 of 71 patients (sensitivity 19.7%), and 12 of 117 control cases were positive for s-p53-Ab (specificity 89.7%). Excluding 12 cases of p16-positive oropharyngeal and nasopharyngeal cancer which were all negative for s-p53-Ab, the sensitivity in early-stage 1-2 cases was 30.0%, which was higher than conventional tumor markers. Conclusions and significance: The s-p53-Ab was not detected in any cases of virus-related cancer in which p53 gene mutations were not involved in carcinogenesis. Since the s-p53-Ab sensitivity was high even in early-stage disease, s-p53-Ab measurement may be useful as an early diagnostic biomarker in patients with oral, p16- oropharyngeal, and hypopharyngeal cancer.
What problem does this paper attempt to address?